|
1
|
Eble JN, Togashi K, Pisani P, et al: Renal
cell carcinoma. Pathology and Genetics of Tumours of the Urinary
System and Male Genital Organs. WHO Classification of Tumours. 7.
Eble JN, Sauter G, Epstein JI and Sesterhenn IA: IARC Press; Lyon:
pp. 12–32. 2004
|
|
2
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
|
|
3
|
Jacobsohn KM and Wood CG: Adjuvant therapy
for renal cell carcinoma. Semin Oncol. 33:576–582. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Janzen NK, Kim HL, Figlin RA and
Belldegrun AS: Surveillance after radical or partial nephrectomy
for localized renal cell carcinoma and management of recurrent
disease. Urol Clin North Am. 30:843–852. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kim WY and Kaelin WG: Role of VHL gene
mutation in human cancer. J Clin Oncol. 22:4991–5004. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Setlur SR, Royce TE, Sboner A, Mosquera
JM, Demichelis F, Hofer MD, Mertz KD, Gerstein M and Rubin MA:
Integrative microarray analysis of pathways dysregulated in
metastatic prostate cancer. Cancer Res. 67:10296–10303. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Maruschke M, Reuter D, Koczan D, Hakenberg
OW and Thiesen HJ: Gene expression analysis in clear cell renal
cell carcinoma using gene set enrichment analysis for
biostatistical management. BJU Int. 108:E29–E35. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Subramanian A, Tamayo P, Mootha VK,
Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub
TR, Lander ES and Mesirov JP: Gene set enrichment analysis: a
knowledge-based approach for interpreting genome-wide expression
profiles. Proc Natl Acad Sci USA. 102:15545–15550. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mootha VK, Lindgren CM, Eriksson KF, et
al: PGC-1alpha-responsive genes involved in oxidative
phosphorylation are coordinately downregulated in human diabetes.
Nat Genet. 34:267–273. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shi J and Walker MG: Gene set enrichment
analysis (GSEA) for interpreting gene expression profiles. Curr
Bioinform. 2:133–137. 2007. View Article : Google Scholar
|
|
11
|
Lenburg ME, Liou LS, Gerry NP, Frampton
GM, Cohen HT and Christman MF: Previously unidentified changes in
renal cell carcinoma gene expression identified by parametric
analysis of microarray data. BMC Cancer. 3:312003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jones J, Otu H, Spentzos D, et al: Gene
signatures of progression and metastasis in renal cell cancer. Clin
Cancer Res. 11:5730–5739. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang Y, Roche O, Yan MS, et al: Regulation
of endocytosis via the oxygen-sensing pathway. Nat Med. 15:319–324.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yusenko MV, Zubakov D and Kovacs G: Gene
expression profiling of chromophobe renal cell carcinomas and renal
oncocytomas by Affymetrix GeneChip using pooled and individual
tumours. Int J Biol Sci. 5:517–527. 2009. View Article : Google Scholar
|
|
15
|
Gumz ML, Zou H, Kreinest PA, et al:
Secreted frizzled-related protein 1 loss contributes to tumor
phenotype of clear cell renal cell carcinoma. Clin Cancer Res.
13:4740–4749. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Brannon AR, Reddy A, Seiler M, et al:
Molecular stratification of clear cell renal cell carcinoma by
consensus clustering reveals distinct subtypes and survival
patterns. Genes Cancer. 1:152–163. 2010. View Article : Google Scholar
|
|
17
|
Stickel J, Weinzierl AO, Hillen N, Drews
O, Schuler MM, Hennenlotter J, Wernet D, Müller CA, Stenzl A,
Rammensee HG and Stevanović S: HLA ligand profiles of primary renal
cell carcinoma maintained in metastases. Cancer Immunol Immunother.
58:1407–1417. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gentleman RC, Carey VJ, Bates DM, et al:
Bioconductor: open software development for computational biology
and bioinformatics. Genome Biol. 5:R802004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gentleman R: Using Categories to Model
Genomic Data. 2009, Available from: https://www.bioconductor.org.
Accessed April 3, 2013
|
|
20
|
Irizarry RA, Hobbs B, Collin F,
Beazer-Barclay YD, Antonellis KJ, Scherf U and Speed TP:
Exploration, normalization, and summaries of high density
oligonucleotide array probe level data. Biostatistics. 4:249–264.
2003. View Article : Google Scholar
|
|
21
|
Gautier L, Cope L, Bolstad BM and Irizarry
RA: affy - analysis of Affymetrix GeneChip data at the probe level.
Bioinformatics. 20:307–315. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Brown BM: A method for combining
non-independent, one-sided tests of significance. Biometrics.
31:987–992. 1975. View
Article : Google Scholar
|
|
23
|
Manoli T, Gretz N, Gröne HJ, Kenzelmann M,
Eils R and Brors B: Group testing for pathway analysis improves
comparability of different microarray datasets. Bioinformatics.
22:2500–2506. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Linehan WM, Srinivasan R and Schmidt LS:
The genetic basis of kidney cancer: a metabolic disease. Nat Rev
Urol. 7:277–285. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yang Y, Valera VA, Padilla-Nash HM, et al:
UOK 262 cell line, fumarate hydratase deficient
(FH−/FH−) hereditary leiomyomatosis renal
cell carcinoma: in vitro and in vivo model of an aberrant energy
metabolic pathway in human cancer. Cancer Genet Cytogenet.
196:45–55. 2010.PubMed/NCBI
|
|
26
|
Xie H, Valera VA, Merino MJ, Amato AM,
Signoretti S, Linehan WM, Sukhatme VP and Seth P: LDH-A inhibition,
a therapeutic strategy for treatment of hereditary leiomyomatosis
and renal cell cancer. Mol Cancer Ther. 8:626–635. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sudarshan S, Sourbier C, Kong HS, et al:
Fumarate hydratase deficiency in renal cancer induces glycolytic
addiction and hypoxia-inducible transcription factor-1alpha
stabilization by glucose-dependent generation of reactive oxygen
species. Mol Cell Biol. 29:4080–4090. 2009. View Article : Google Scholar
|
|
28
|
Baysal BE, Ferrell RE, Willet-Brozick JE,
et al: Mutations in SDHD, a mitochondrial complex II gene, in
hereditary paraganglioma. Science. 287:848–851. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Vanharanta S, Buchta M, McWhinney SR, et
al: Early-onset renal cell carcinoma as a novel extraparaganglial
component of SDHB-associated heritable paraganglioma. Am J Hum
Genet. 74:153–159. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tsukita S, Furuse M and Itoh M:
Multifunctional strands in tight junctions. Nat Rev Mol Cell Biol.
2:285–293. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mitic LL and Anderson JM: Molecular
architecture of tight junctions. Annu Rev Physiol. 60:121–142.
1998. View Article : Google Scholar
|
|
32
|
Kimura Y, Shiozaki H, Hirao M, Maeno Y,
Doki Y, Inoue M, Monden T, Ando-Akatsuka Y, Furuse M, Tsukita S and
Monden M: Expression of occludin, tight-junction-associated
protein, in human digestive tract. Am J Pathol. 151:45–54.
1997.PubMed/NCBI
|
|
33
|
Krämer F, White K, Kubbies M, Swisshelm K
and Weber BH: Genomic organization of claudin-1 and its assessment
in hereditary and sporadic breast cancer. Hum Genet. 107:249–256.
2000.PubMed/NCBI
|
|
34
|
Tokés AM, Kulka J, Paku S, Szik A, Páska
C, Novák PK, Szilák L, Kiss A, Bögi K and Schaff Z: Claudin-1, −3
and −4 proteins and mRNA expression in benign and malignant breast
lesions: a research study. Breast Cancer Res. 7:R296–R305.
2005.
|
|
35
|
Hewitt KJ, Agarwal R and Morin PJ: The
claudin gene family: expression in normal and neoplastic tissues.
BMC Camcer. 1862006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Long H, Crean CD, Lee WH, Cummings OW and
Gabig TG: Expression of Clostridium perfringens enterotoxin
receptors claudin-3 and claudin-4 in prostate cancer epithelium.
Cancer Res. 61:7878–7881. 2001.
|
|
37
|
Morin PJ: Claudin proteins in human
cancer: promising new targets for diagnosis and therapy. Cancer
Res. 65:9603–9606. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Asou N: 2. All-trans retinoic acid in the
treatment of acute promyelocytic leukemia. Intern Med. 46:91–93.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Motzer RJ, Schwartz L, Law TM, Murphy BA,
Hoffman AD, Albino AP, Vlamis V and Nanus DM: Interferon alfa-2a
and 13-cis-retinoic acid in renal cell carcinoma: antitumor
activity in a phase II trial and interactions in vitro. J Clin
Oncol. 13:1950–1957. 1995.PubMed/NCBI
|
|
40
|
Recchia F, Saggio G, Amiconi G, Di Blasio
A, Cesta A, Candeloro G, Necozione S, Fumagalli L and Rea S:
Multicenter phase II study of chemo-immunotherapy in the treatment
of metastatic renal cell carcinoma. J Immunother. 30:448–454. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Boorjian SA, Milowsky MI, Kaplan J, Albert
M, Cobham MV, Coll DM, Mongan NP, Shelton G, Petrylak D, Gudas LJ
and Nanus DM: Phase 1/2 clinical trial of interferon alpha2b and
weekly liposome-encapsulated all-trans retinoic acid in patients
with advanced renal cell carcinoma. J Immunother. 30:655–662. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Motzer RJ, Murphy BA, Bacik J, Schwartz
LH, Nanus DM, Mariani T, Loehrer P, Wilding G, Fairclough DL, Cella
D and Mazumdar M: Phase III trial of interferon alfa-2a with or
without 13-cis-retinoic acid for patients with advanced renal cell
carcinoma. J Clin Oncol. 18:2972–2980. 2000.PubMed/NCBI
|
|
43
|
Aass N, De Mulder PH, Mickisch GH, Mulders
P, van Oosterom AT, van Poppel H, Fossa SD, de Prijck L and
Sylvester RJ: Randomized phase II/III trial of interferon Alfa-2a
with and without 13-cis-retinoic acid in patients with progressive
metastatic renal cell carcinoma: the European Organisation for
Research and Treatment of Cancer Genito-Urinary Tract Cancer Group
(EORTC 30951). J Clin Oncol. 23:4172–4178. 2005.
|
|
44
|
Atzpodien J, Kirchner H, Rebmann U, et al:
Interleukin-2/interferon-alpha2a/13-retinoic acid-based
chemoimmunotherapy in advanced renal cell carcinoma: results of a
prospectively randomised trial of the German Cooperative Renal
Carcinoma Chemoimmunotherapy Group (DGCIN). Br J Cancer.
95:463–469. 2006. View Article : Google Scholar
|
|
45
|
Elsässer-Beile U, Grussenmeyer T,
Gierschner D, Schmoll B, Schultze-Seemann W, Wetterauer U and
Schulte Mönting J: Semiquantitative analysis of Th1 and Th2
cytokine expression in CD3+, CD4+, and
CD8+ renal-cell-carcinoma-infiltrating lymphocytes.
Cancer Immunol Immunother. 48:204–208. 1999.PubMed/NCBI
|
|
46
|
Finke JH, Rayman P, Edinger M, Tubbs RR,
Stanley J, Klein E and Bukowski R: Characterization of a human
renal cell carcinoma specific cytotoxic CD8+ T cell
line. J Immunother (1991). 11:1–11. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Gaudin C, Dietrich PY, Robache S, Guillard
M, Escudier B, Lacombe MJ, Kumar A, Triebel F and Caignard A: In
vivo local expansion of clonal T cell subpopulations in renal cell
carcinoma. Cancer Res. 55:685–690. 1995.PubMed/NCBI
|
|
48
|
Schwaab T, Schned AR, Heaney JA, Cole BF,
Atzpodien J, Wittke F and Ernstoff MS: In vivo description of
dendritic cells in human renal cell carcinoma. J Urol. 162:567–573.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zagzag D, Krishnamachary B, Yee H, Okuyama
H, Chiriboga L, Ali MA, Melamed J and Semenza GL: Stromal
cell-derived factor-1alpha and CXCR4 expression in hemangioblastoma
and clear cell-renal cell carcinoma: von Hippel-Lindau
loss-of-function induces expression of a ligand and its receptor.
Cancer Res. 65:6178–6188. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Schrader AJ, Lechner O, Templin M, et al:
CXCR4/CXCL12 expression and signalling in kidney cancer. Br J
Cancer. 86:1250–1256. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Balkwill F: The significance of cancer
cell expression of the chemokine receptor CXCR4. Semin Cancer Biol.
4:171–179. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Kucia M, Jankowski K, Reca R, Wysoczynski
M, Bandura L, Allendorf DJ, Zhang J, Ratajczak J and Ratajczak MZ:
CXCR4-SDF-1 signalling, locomotion, chemotaxis and adhesion. J Mol
Histol. 35:233–245. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Zlotnik A: Chemokines in neoplastic
progression. Semin Cancer Biol. 14:181–185. 2004. View Article : Google Scholar
|
|
54
|
Burger JA and Kipps TJ: CXCR4: a key
receptor in the crosstalk between tumor cells and their
microenvironment. Blood. 107:1761–1767. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Wang L, Wang L, Yang B, Yang Q, Qiao S,
Wang Y and Sun Y: Strong expression of chemokine receptor CXCR4 by
renal cell carcinoma cells correlates with metastasis. Clin Exp
Metastasis. 26:1049–1054. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Reckamp KL, Strieter RM and Figlin RA:
Chemokines as therapeutic targets in renal cell carcinoma. Expert
Rev Anticancer Ther. 8:887–893. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Darnell JE Jr, Kerr IM and Stark GR:
Jak-STAT pathways and transcriptional activation in response to
IFNs and other extracellular signaling proteins. Science.
264:1415–1421. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Shang D, Liu Y, Ito N, Kamoto T and Ogawa
O: Defective Jak-Stat activation in renal cell carcinoma is
associated with interferon-alpha resistance. Cancer Sci.
98:1259–1264. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Lundqvist A, Abrams SI, Schrump DS,
Alvarez G, Suffredini D, Berg M and Childs R: Bortezomib and
depsipeptide sensitize tumors to tumor necrosis factor-related
apoptosis-inducing ligand: a novel method to potentiate natural
killer cell tumor cytotoxicity. Cancer Res. 66:7317–7325. 2006.
View Article : Google Scholar
|
|
60
|
Wu XX, Zeng Y, Jin XH and Kakehi Y:
Enhanced susceptibility of adriamycin-treated human renal cell
carcinoma cells to lysis by peripheral blood lymphocytes and tumor
infiltrating lymphocytes. Oncol Rep. 18:353–359. 2007.
|
